Current Cardiology Reports最新文献

{"title":"Psychological Interventions for Reducing Distress in Patients with Cardiac Arrhythmias.","authors":"Josefin Särnholm, Allison E Gaffey, Meghan Reading Turchio, Angelo Biviano, Matthew M Burg","doi":"10.1007/s11886-025-02253-4","DOIUrl":"10.1007/s11886-025-02253-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cardiac arrhythmias, including atrial fibrillation (AF) and ventricular arrhythmias (VA), are associated with anxiety, depression, and poor quality of life (QoL). These and related aspects of psychological health significantly influence the clinical course and prognosis of arrhythmia patients, yet their integration into routine arrhythmia care remain limited. This focused review examines the use of psychological interventions, particularly cognitive behavioral therapy (CBT), in addressing psychological health in arrhythmia patients and discusses strategies for integrating these interventions into arrhythmia care.</p><p><strong>Recent findings: </strong>CBT has demonstrated efficacy in reducing anxiety, depression, cardiac-related fears, and avoidance behaviors while improving QoL in arrhythmia patients. Further research is necessary to evaluate the effectiveness of these interventions in real-world care systems. Multidisciplinary care collaborations are essential for advancing the integration of psychological health within arrhythmia care. Integrating CBT for psychological health into arrhythmia care can improve clinical outcomes.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"102"},"PeriodicalIF":3.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Heart: Exploring Extracardiac Manifestations in Cardiac Amyloidosis for Early Diagnosis.","authors":"Marcus Saldanha, Lu Kun Chen, Joshua Solomon, Kristina Cunanan, Francois Tournoux, Rami Massie, Michael Chetrit","doi":"10.1007/s11886-025-02251-6","DOIUrl":"https://doi.org/10.1007/s11886-025-02251-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review examines extracardiac manifestations of cardiac amyloidosis and their potential role in early diagnosis and management. Multisystem involvement, including musculoskeletal, peripheral nervous system, and other extracardiac findings are highlighted to serve as red flags for earlier detection.</p><p><strong>Recent findings: </strong>Early screening for high-risk individuals over 50 with CTS or spinal stenosis could enable earlier intervention. Peripheral neuropathy and CTS often precede cardiac involvement by 5-10 years, while spinal stenosis can precede it by 5-15 years. Other indicators include biceps tendon rupture, trigger finger, and gastrointestinal issues. MRI shows promise in detecting amyloid-related changes, especially wrist MRI. More studies are needed. Recognizing extracardiac findings may enable earlier diagnosis and intervention before significant cardiac dysfunction. Current workflows use extracardiac manifestations to detect cardiac amyloidosis after cardiac involvement. Integrating these insights earlier could identify amyloidosis years before cardiac issues, improving screening, patient outcomes, and guiding future therapies.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"105"},"PeriodicalIF":3.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Management of Atrial Arrhythmias in Cancer Patients.","authors":"Robert Monsour, Angie Seo, Nicholas Wilcox, Michael G Fradley","doi":"10.1007/s11886-025-02261-4","DOIUrl":"10.1007/s11886-025-02261-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Atrial arrhythmias are an increasingly recognized cardiovascular issue for cancer patients and can lead to increased morbidity and mortality independent of the oncologic prognosis. This review highlights the epidemiology of atrial arrhythmias in cancer patients including risk factors and arrhythmogenic cancer treatments as well as the current state of knowledge regarding the prevention and treatment of atrial arrhythmias in this population.</p><p><strong>Recent findings: </strong>There appears to be bidirectional risk of atrial arrhythmias and cancer, with increased rates of atrial fibrillation identified in cancer patients but also increased cancer in patients with know atrial fibrillation. Moreover, as the cancer treatment landscape has continued to evolve, many novel treatments have been shown to be arrhythmogenic. Currently, the recommendations for the prevention and treatment of cancer associated arrhythmias are the same as the general population. Atrial arrhythmias are common in cancer patients due to multiple factors including shared risk factors and the cancer treatments themselves. Additional research is essential to better understand risk and also to provide cancer-specific recommendations for the prophylaxis and management of atrial arrhythmias and their associated thromboembolic complications.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"103"},"PeriodicalIF":3.1,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scores for Risk Stratification of Pericarditis.","authors":"Massimo Imazio, Alessandro Andreis, Allan Klein, George Lazaros, Emilia Lazarou, Valentino Collini","doi":"10.1007/s11886-025-02259-y","DOIUrl":"https://doi.org/10.1007/s11886-025-02259-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review current available risk scores for pericarditis risk stratification.</p><p><strong>Recent findings: </strong>Four recent published scores have provided new clinical tools for the evaluation of risk of recurrent pericarditis after a first episode or acute pericarditis (Athens score) or complicated pericarditis (Torino score), diagnosis of pericarditis (pericarditis INFLA-score) or clinical remission (Cleveland Clinic/ Klein score). Recent scores for pericarditis diagnosis or risk stratification have been developed by tertiary referral centres with the aim of improving risk stratification and diagnosis and allowing an individualized approach for treatment and follow-up identifying the high-risk group of patients. While these scores are helpful in developing a more evidence-based approach for risk stratification of pericarditis, they have some limitations (single-centre, tertiary centres with referral bias, relatively limited sample size, new therapies not always included) and require further validation before clinical implementation in large unselected populations.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"101"},"PeriodicalIF":3.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Acetazolamide in People with Decompensated Heart Failure: A Systematic Review and Meta-Analysis.","authors":"Johana Elizabeth Erazo-Castillo, Juan Camilo Ramos-Picón, Johana Patricia Galván-Barrios, Yelson Alejandro Picón-Jaimes","doi":"10.1007/s11886-025-02257-0","DOIUrl":"https://doi.org/10.1007/s11886-025-02257-0","url":null,"abstract":"<p><strong>Introduction: </strong>Acetazolamide is used in heart failure to improve diuresis and reduce volume overload. It acts as a diuretic in the proximal tubule, inhibiting the reabsorption of bicarbonate, water, and sodium.</p><p><strong>Methods: </strong>A systematic review with meta-analysis of studies between 2014 and 2024 was conducted to evaluate the efficacy of Acetazolamide in decompensated heart failure compared to other drugs. Observational studies and clinical trials were considered. Searches were conducted in Medline, Scopus, Web of Science, CENTRAL and the World Health Organization clinical trials registry. A sensitivity analysis was performed for each outcome.</p><p><strong>Results: </strong>The addition of Acetazolamide to standard diuretic treatment in patients with heart failure produces greater diuretic efficiency, a reduction in fluid balance, and a promotion of sodium loss. A decrease in Pro-BNP-NT levels and an improvement in volume overload symptoms have also been observed. The most notable result was natriuresis, where a mean difference in favour of Acetazolamide was observed: MD of 56.98 with a 95% CI (27.7-86.2).</p><p><strong>Conclusions: </strong>Acetazolamide may be an effective option for managing congestion in patients with heart failure, improving the signs and symptoms of volume overload. Its effect on mean diuresis is comparable to or slightly higher than that observed with other diuretics. In addition, it induces favourable changes in sodium excretion, optimizing the management of electrolyte balance.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"99"},"PeriodicalIF":3.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovating the Gold Standard: The Emerging Role of Echocardiographic Stress Testing in the Classification, Stratification, and Prognostication in Pulmonary Vascular Disease.","authors":"Garrett Goldin, Hoda Mombeini, Valentina Mercurio, Steven Hsu, Matthew R Lammi, Stephen C Mathai, Luna Gargani, Monica Mukherjee","doi":"10.1007/s11886-025-02242-7","DOIUrl":"10.1007/s11886-025-02242-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>The goal of this review is to examine the evolving role of exercise stress echocardiography (ESE) in the diagnosis and management of pulmonary vascular diseases (PVD), particularly pulmonary hypertension (PH). We sought to explore how ESE can assess dynamic cardiopulmonary interactions, distinguish between PH subtypes, evaluate right ventricular (RV) contractile function and reserve, and provide a noninvasive alternative for early detection, risk stratification, and clinical decision-making in patients with unexplained dyspnea and PVD.</p><p><strong>Recent findings: </strong>Although right heart catheterization (RHC) remains the diagnostic gold standard, ESE has emerged as a promising noninvasive tool to assess dynamic changes in ventricular function, interventricular interactions, cardiopulmonary hemodynamics, and systemic circulation under stress conditions. Beyond traditional ischemic evaluation, ESE has demonstrated potential for identifying underlying causes of dyspnea in populations with rising cardiopulmonary risk factors such as aging, cardiovascular disease, obesity, COPD, and left heart failure. Recent studies highlight the ability of ESE to differentiate PH subtypes and offer prognostic insights. However, important knowledge gaps remain, particularly regarding standardized protocols and interpretation across different PH groups. Our review affirms that ESE offers a valuable, noninvasive approach for the early identification and risk stratification of PH, complementing or, in selected cases, providing an alternative to invasive hemodynamics. By evaluating dynamic cardiopulmonary interactions and RV reserve, ESE can refine diagnosis, improve clinical management, and potentially guide earlier therapeutic interventions in at-risk patients. Future research should focus on standardizing ESE methodologies, validating noninvasive surrogate measures of hemodynamics, and expanding its role in clinical practice to optimize the care of patients with PVD.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"100"},"PeriodicalIF":3.1,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Artificial Intelligence on Women's Cardiovascular Disease Care.","authors":"Jina Chung, Jenica Thangathurai, Sharon Andrade-Bucknor, Susmita Parashar, Karina Gonzalez Carta, Marc Epp, Carol Ma","doi":"10.1007/s11886-025-02250-7","DOIUrl":"10.1007/s11886-025-02250-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>To review current artificial intelligence (AI) applications impacting cardiovascular disease care in women.</p><p><strong>Recent findings: </strong>Women differ from men in cardiovascular anatomy, physiology, presentation, and treatment response, yet face disparities due to underrepresentation in trials and referral bias. AI applications offer promising tools to close these gaps by enhancing screening, diagnosis, monitoring, and treatment. This review explores female representation, outcomes, and future directions in AI-driven advancements in coronary artery disease, heart failure with preserved ejection fraction, valvular heart disease, ischemic and nonischemic cardiomyopathies, including peripartum cardiovascular disease. AI holds the potential to transform cardiovascular disease care in women by leveraging multidimensional datasets for sex-specific screening, risk prediction, prognostic phenomapping and therapeutic decision support. Expanding female representation and integrating sex-specific factors in AI research are essential to minimize bias, ensure robust external validation and enable equitable, scalable implementation.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"98"},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Stent Restenosis: Incidence, Mechanisms, and Treatment Options.","authors":"Michael Sola, Zachary Tugaoen, Jessica Willis, George A Stouffer","doi":"10.1007/s11886-025-02249-0","DOIUrl":"https://doi.org/10.1007/s11886-025-02249-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>To provide an overview of up-to-date treatment practices for in-stent restenosis (ISR).</p><p><strong>Recent findings: </strong>ISR is treated with similar effectiveness by paclitaxel drug coated balloons and second-generation drug eluting stents. Sirolimus coated balloons are an emerging technology that requires further investigation. The management of ISR remains challenging even with the newest generation of drug-eluting stents. The use of intravascular imaging is highly recommended to identify the mechanisms of stent failure and to tailor the method of treatment, whether it is plain old balloon angioplasty, plaque/calcium modifying tools such as intravascular lithotripsy or rotational atherectomy, additional drug eluting stents, or drug coated balloons. Paclitaxel drug coated balloons are the most recent technological advancement which has provided an option to treat ISR that doesn't require further layers of metal. Currently, other drug coatings are being studied but it is unclear whether these balloons are as effective as paclitaxel coated balloons, with ongoing trials designed to answer this question.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"96"},"PeriodicalIF":3.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage Containing Cardiac Organoids for Studying Inflammatory Programmes Driving Cardiovascular Disease.","authors":"Christopher R Hunter, James E Hudson","doi":"10.1007/s11886-025-02246-3","DOIUrl":"10.1007/s11886-025-02246-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>There are specialised heart populations of macrophages that arise from diverse origins in vivo. Incorporating these into human pluripotent derived cardiac organoids (hCOs) provides a new method to study their role in cardiac function and disease. Herein, we review this topic and propose future directions.</p><p><strong>Recent findings: </strong>Macrophages are particularly important and exert positive and negative influences during the pathogenesis of disease, and resolution after injury. The heart microenvironment imprints specific functions into cardiac macrophages including efferocytosis of mitochrondria, control of electrical conduction and control of stromal and parenchymal homeostasis in the heart. Initial studies using hCOs has shown that incorporating macrophages improves maturation and disease modelling. We highlight key in vivo functions have been shown by macrophages in hCOs. However, outstanding questions remain and represent exciting research avenues in the future. An important avenue being incorporation of the macrophage phenotypic diversity recently shown in vivo.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"97"},"PeriodicalIF":3.1,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Regeneration and Repair in Zebrafish and Mammalian Models.","authors":"Stanislao Igor Travisano, Ching-Ling Lien","doi":"10.1007/s11886-025-02235-6","DOIUrl":"10.1007/s11886-025-02235-6","url":null,"abstract":"<p><strong>Aim: </strong>In this review, we discuss the regenerative processes in the heart, focusing on non-cardiomyocyte cell populations (fibroblasts, immune cells, and endothelial cells) in zebrafish and mammals. We highlight the role of signaling pathways in heart repair and the potential for therapeutic strategies based on these mechanisms.</p><p><strong>Purpose of review: </strong>The review examines key molecular and cellular mechanisms in cardiac regeneration, with a focus on fibroblasts, immune modulation, and endothelial function, to identify strategies for enhancing heart repair.</p><p><strong>Recent findings: </strong>Recent advancements in characterization of different cell types at the single cell level, along with the discovery of regeneration enhancer elements, have opened new avenues for cardiac regeneration. Targeting the epicardium, along with fibroblast activation, immune modulation, and endothelial signaling, may offer therapeutic strategies to enhance heart regeneration by supporting cardiomyocytes in mice and humans. While non-cardiomyocytes in zebrafish contribute to heart regeneration, in mice and humans, these cells often drive fibrosis instead. Understanding these species-specific differences is crucial for optimizing therapeutic approaches to treat cardiac injury and prevent fibrosis.</p>","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"95"},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}